Harvoni Treatment Porphyria Cutanea Tarda

Phase 2 Completed 23 enrolled Wake Forest University Health Sciences Gilead Sciences · collab National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · collab National Institutes of Health (NIH) · collab

NaSingle-groupOpen-labelTreatment

Summary

In the medical literature there case reports that Harvoni improves symptoms in patients with PCT. However, this has never been systematically tested. Therefore, the purpose of this study is to assess whether Harvoni alone is an effective therapy of active PCT in patients with Chronic Hepatitis C.

Timeline

Start: 2017-09-06
Primary completion: 2022-03-04
Completion: 2022-03-04

Publications

Bonkovsky HL, Rudnick SP, Ma CD, Overbey JR, Wang K, Faust D, Hallberg C, Hedstrom K, Naik H, Moghe A, Anderson KE. Ledipasvir/Sofosbuvir Is Effective as Sole Treatment of Porphyria Cutanea Tarda with Chronic Hepatitis C. Dig Dis Sci. 2023 Jun;68(6):2738-2746. doi: 10.1007/s10620-023-07859-8. Epub 2023 Feb 22.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ledipasvir	Small molecule	90 mg	Oral
Subject	Sofosbuvir	Small molecule	400 mg	Oral

Harvoni Treatment Porphyria Cutanea Tarda

Summary

Timeline

Publications

Drugs

Indications